Browse the evidence

A 3-month calorie-restricted ketogenic diet (KD) produces significantly greater weight loss than a calorie-restricted Mediterranean diet (MedDiet) in adults with obesity.

To lose more weight than a standard Mediterranean diet in 3 months, switch to a ketogenic diet with a 600-calorie daily deficit. This means eating very few carbs (5% of calories), moderate protein (30%), and high fat (65%). Ensure you are consuming enough calories to maintain basic function but below your maintenance level.

Modified Alternate-Day Fasting (mADF) produces significantly greater weight loss than a calorie-restricted Mediterranean diet (MedDiet) in adults with obesity.

Try modified alternate-day fasting: eat normally (but within your calorie limit) 4 days a week, and restrict calories to 400-800 on the other 3 days. This approach may yield better weight loss than a standard Mediterranean diet.

Late Time-Restricted Eating (lTRE) with an 8-hour window (2 pm - 10 pm) produces significantly greater weight loss than a calorie-restricted Mediterranean diet (MedDiet) in adults with obesity.

Try late time-restricted eating: restrict your eating to an 8-hour window from 2 pm to 10 pm. Ensure you are eating a balanced diet (45% carbs, 20% protein, 35% fat) with a 600-calorie daily deficit. This may yield better weight loss than a standard Mediterranean diet.

Weekly administration of semaglutide at 2.4 mg induces significant weight loss (mean 14.9%) and improves glycemic control (HbA1c < 7.0% in 57-74% of patients) in adults with obesity or type 2 diabetes, with effects proportional to dose and duration.

If you have obesity or type 2 diabetes, weekly semaglutide (2.4 mg for weight loss, 1-1.0 mg for diabetes) is a highly effective treatment that can lead to significant weight loss (up to 15%) and better blood sugar control. While nausea and vomiting are common side effects, they are usually mild and temporary, and weight loss often occurs regardless of whether you experience them. An oral version is also available if you prefer to avoid injections. Discuss this with your doctor to see if it's right for you.

Tirzepatide produces significantly greater weight loss than semaglutide in overweight and obese adults, with a standardized mean difference of 0.75 favoring tirzepatide.

If you are choosing between tirzepatide and semaglutide for weight loss, current direct comparative evidence suggests tirzepatide may lead to greater weight reduction. This benefit comes with a dual-hormone mechanism (GIP/GLP-1) and requires weekly injections. You should expect potential gastrointestinal side effects during dose increases, which are usually manageable. Combining the medication with diet and exercise will likely enhance results.

Tirzepatide significantly increases the odds of achieving clinically meaningful weight loss (≥10% body weight reduction) compared to semaglutide.

A key benefit of tirzepatide over semaglutide is the increased likelihood of losing 10% or more of your body weight, a threshold often associated with significant health improvements. This makes tirzepatide a potentially more effective option if your primary goal is substantial weight reduction. Discuss with your provider whether this higher efficacy profile aligns with your health goals.

GLP-1 receptor agonists (e.g., liraglutide) produce significant weight loss (mean 8.4 kg over 56 weeks) by slowing gastric emptying and activating central satiety pathways, with 33.1% of patients achieving >10% body weight loss.

If you have obesity (BMI > 30, or > 27 with health issues), ask your doctor about GLP-1 agonists like liraglutide. This medication, taken daily, has been shown in clinical trials to help patients lose an average of 8.4 kg over a year, with many losing over 10% of their body weight. It works by slowing digestion and signaling fullness to your brain.

Tirzepatide significantly reduces ad libitum energy intake and body weight in adults with overweight or obesity, primarily by decreasing fasting appetite, food cravings, and disinhibition rather than increasing cognitive restraint.

Tirzepatide, a once-weekly injectable medication, significantly reduces food intake and body weight in adults with overweight or obesity. It works by lowering appetite, reducing food cravings, and decreasing the tendency to overeat, rather than by increasing willpower or cognitive restraint. While gastrointestinal side effects like nausea are common, they are often mild and tend to occur more frequently after the first injection. This suggests that tirzepatide can be an effective tool for managing energy intake and promoting weight loss, particularly for those who struggle with appetite and cravings.

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) produce significant weight loss (6–30%+ TBWL) and improve fertility outcomes (spontaneous conception, IVF pregnancy rates) in women with obesity and PCOS when used in the preconception period.

If you have obesity and are trying to conceive, GLP-1 medications (like Wegovy or Zepbound) are highly effective for weight loss and improving fertility, especially if you have PCOS. You must stop taking them 2 months before you try to conceive to ensure the drug is out of your system. Work with your doctor to manage side effects and costs.

Endurance athletes require a daily protein intake of approximately 1.8 g/kg body mass per day, which may increase to >2.0 g/kg/day during carbohydrate-restricted training or on rest days.

Aim for 1.8 grams of protein per kilogram of body weight every day. If you are doing low-carb training sessions or taking rest days, bump this up to over 2.0 grams per kilogram. This helps your body repair muscle and replace amino acids lost during exercise.

Dual GLP-1/GIP receptor agonists (e.g., tirzepatide) produce significantly greater weight loss and glycemic control than selective GLP-1 receptor agonists by synergistically targeting both incretin pathways.

If you have T2DM or obesity, dual GLP-1/GIP agonists like tirzepatide are currently the most effective pharmacological option for weight loss and blood sugar control, outperforming older GLP-1 drugs. They are taken as a once-weekly injection. Discuss with your doctor if this advanced therapy is appropriate for your specific health profile.

Multi-receptor incretin drugs (Tirzepatide, Retatrutide, Mazdutide, Survodutide) produce substantial weight loss (>8kg) and glycemic control (HbA1c reduction >1%) in adults with overweight/obesity, with non-diabetic populations showing more pronounced effects than those with type 2 diabetes.

If you have overweight or obesity, multi-receptor incretin drugs like Tirzepatide or Retatrutide are highly effective for significant weight loss (often >10kg) and improving blood sugar control. These benefits are even more pronounced if you do not have type 2 diabetes. While gastrointestinal side effects are common, serious safety risks are not significantly higher than placebo. Consult a healthcare provider to determine if these medications are appropriate for your specific health profile.

Achieving early weight loss of ≥10% body weight in newly diagnosed type 2 diabetes significantly increases the likelihood of diabetes remission and sustains glycaemic improvements compared to losing <10%.

For newly diagnosed type 2 diabetes, aiming for a 10% body weight loss within the first five years is a critical threshold. This specific magnitude of loss is strongly associated with a 4-fold increase in the chance of achieving diabetes remission and sustained lower HbA1c levels compared to smaller weight losses.

GLP-1 Receptor Agonists (specifically Semaglutide) induce significant weight loss (10-15%) and improve metabolic and endocrine markers (including menstrual regularity and insulin sensitivity) in women with PCOS, although long-term sustainability requires continued treatment.

Semaglutide (a GLP-1 RA) is an effective treatment for women with PCOS who are obese and haven't succeeded with lifestyle changes alone. It promotes significant weight loss (approx. 11-15 kg) and can restore menstrual regularity and improve insulin sensitivity. However, stopping the medication often leads to partial weight regain, suggesting it may need to be a long-term therapy for sustained benefits.

Replacing ultra-processed foods with minimally processed foods leads to significant weight loss and reduced energy intake even when macronutrients and calories are matched.

Stop eating ultra-processed foods. The paper shows that even if you eat the same number of calories, UPFs make you eat more because they are hyper-palatable. Switch to minimally processed foods to naturally reduce calorie intake and lose weight.

Replacing saturated fats with polyunsaturated fats (PUFAs) reduces cardiovascular event risk by 17% and offers greater protection than replacing them with carbohydrates.

Replace saturated fats (found in animal products and tropical oils) with polyunsaturated fats (found in nuts, seeds, and vegetable oils). This substitution reduces your risk of cardiovascular events by 17% and is more effective for heart health than replacing fat with carbohydrates.

High intake of simple sugars and refined grains is strongly associated with long-term weight gain and type 2 diabetes, particularly through sugary beverages.

Cut back on sugary beverages, white bread, white rice, and candy. These foods are strongly linked to weight gain and type 2 diabetes. Replace them with whole grains and high-fiber foods to improve your metabolic health.

High protein intake (up to 1.6 g/kg/day) combined with strength training significantly improves muscle mass and strength in middle-aged and older adults.

If you are strength training, aim for 1.6 g of protein per kg of body weight per day. This amount, combined with strength training, significantly improves muscle mass and strength, especially in older adults.

Peri-operative essential amino acid (EAA) supplementation significantly reduces muscle atrophy in quadriceps and hamstring muscles following total joint arthroplasty.

If you are having knee or hip replacement surgery, ask your care team about essential amino acid (EAA) or protein supplementation. The evidence suggests this helps preserve muscle mass in your legs during recovery, which is critical for mobility. While it may not instantly boost strength, it prevents the rapid muscle loss common after surgery.

Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, produces superior mean weight loss (up to 24.2%) and metabolic improvements compared to placebo and existing dual agonists in phase 2 trials for obesity and type 2 diabetes.

Retatrutide is a once-weekly injection that targets three hormones to significantly reduce body weight and improve blood sugar control. In clinical trials, it led to an average 24% weight loss in people with obesity over 48 weeks. Common side effects like nausea are manageable with dose titration. It is currently in phase 3 trials for broader approval.

Lifestyle modification, specifically weight loss of >5-10% and regular physical activity, is a cornerstone for improving liver fat and cardiovascular health in MASLD.

Aim for at least 5% weight loss and 150 minutes of exercise per week. This reduces liver fat. Losing 7-10% or more can further reduce inflammation and fibrosis. This is the foundation of MASLD treatment.

Tirzepatide induces significant weight reduction in individuals with obesity caused by pathogenic MC4R mutations, achieving efficacy comparable to non-carriers.

If you have obesity caused by an MC4R mutation, tirzepatide is a highly effective treatment option. Clinical data shows you will likely lose a significant amount of weight (around 18%) over 72 weeks, similar to people without this genetic mutation. Because lifestyle changes alone are often insufficient for this specific genetic profile, pharmacological intervention with tirzepatide is recommended to manage severe obesity and its complications.

Exercise training (ET), including high-intensity interval training (HIIT) and moderate-intensity continuous training, improves functional status, exercise capacity, and quality of life in HFpEF patients.

If you have HFpEF, engage in regular exercise training, including high-intensity interval training (HIIT) or moderate-intensity continuous training. This improves your exercise capacity, quality of life, and heart function. It is safe and recommended by guidelines.

Lifestyle interventions, including dietary management (DASH/SDR, Low-Energy Diet) and exercise training, improve clinical outcomes in obese HFpEF patients.

Adopt a heart-healthy lifestyle, including a DASH or low-energy diet and regular exercise training. These interventions are the cornerstone of HFpEF management and can reduce hospital readmissions and improve exercise capacity.